November 15, 2016

Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases

Read More
November 03, 2016

Selexis and Xencor Enter Strategic Agreement, Strengthening Existing Relationship for Multi-Specific Antibody Cell Line Development

Read More
October 25, 2016

Selexis SA Inks Commercial Cell Line License Agreement with ImmuNext, Inc.  for Anti-CD40L Antibody Being Developed for Treatment of Chronic Autoimmune Disorders

Read More
October 10, 2016

Selexis SA Announces Participation at Two Upcoming Industry Conferences

Read More
October 06, 2016

Selexis Chairman and CEO Dr. Igor Fisch Receives Prestigious Award for Excellence in Leadership from BioProcess International

Read More
September 22, 2016

Selexis SA and IAVI Expand Collaboration to Advance Multiple HIV Vaccine Candidates Toward Clinical Testing

Read More
September 07, 2016

Selexis SA Enters into Commercial Cell Line License Agreement with Pieris Pharmaceuticals for Immuno-Oncology Bispecific Drug Candidate

Read More
July 27, 2016

ASLAN Pharmaceuticals Enters Service Agreement with Selexis SA for Development of a Proprietary Cell Line for Expression of ASLAN004

Read More
July 07, 2016

Turgut Ilaclari A.S. and Selexis SA Sign Service and Commercial Agreements to Progress Development of Biosimilar Products

Read More
June 26, 2016

Symphogen A/S Advances Sym015 into Clinical Development Using Selexis SGE (Selexis Genetic Elements)

Read More
June 21, 2016

Progenics Pharmaceuticals, Inc. Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform

Read More
June 02, 2016

Liomont Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform

Read More
April 17, 2016

Selexis SA Launches SURE CHO-Mplus Libraries

Read More
March 31, 2016

Selexis SA Announces Spring 2016 Conference Schedule

Read More